Daiichi Sankyo announces marketing approval for treatment
19 November 2008 00:00 in Pharmaceutical Company Product News
Daiichi Sankyo has announced it has received marketing approval for Sevikar, a fixed dose combination treatment for essential hypertension.
The obtaining of the authorisation follows the green light being given in Holland, France, Spain, Belgium and the UK.
Reinhard Bauer, chief executive officer at Daiichi Sankyo Europe, said high blood pressure is a major health concern in Europe and the world.
He added: "Sevikar will allow physicians to help challenging patients reach and maintain their blood pressure goal, reducing the risks of cardiovascular disease and ultimately helping to reduce the severe financial strains on health authorities."
The drug is a once-daily single pill fixed dose combination of Olmersartan and Amlodipine.
Studies showed it successfully treated patients with uncontrolled hypertension.
The condition may be present in almost one in three of the adult population and can result in cardiovascular disease.
Earlier this month, Daiichi-Sankyo announced it had completed the takeover of India's Ranbaxy Laboratories, buying a 63.9 per cent stake for 199.8 billion Indian rupees (2.66 billion pounds).
Founded in Japan, Sankyo launched the digestive enzyme Taka-Diastase in 1894.
It then joined with Daiichi Pharmaceutical Co in 2005 and started operations of its European organisation, Daiichi Sankyo Europe, in 2006.
Other news stories from 19/11/2008
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency